News

New cancer collaborations
Enlarge image

BusinessFranceSwitzerland

New cancer collaborations

30.01.2013 - Swiss 4-Antibody and Ludwig Institute will expand their cooperation, while Curie-Cancer and Genosplice Technology inked a cancer genomics pact.

The two new cancer collaborations were kicked-off yesterday. The French bioinformatics expert Genosplice Technology and the tech-transfer arm of Paris-based Institut Curie aim at developing high value-added cancer genomic approaches. GenoSplice will gain access to several Curie-Cancer technology platforms and research programmes and will contribute to the development of new products against cancer through genome mapping using its bioinformatics expertise. The partners aim to define a genomic map for prostate cancer including pathways and therapeutic options. In a second project the French will seek response biomarkers for a preclinical peptide that already has been proven effective in mouse xenograft experiments. 

On the same day, Swiss 4-Antibody AG and US-based Ludwig Institute expanded its existing cancer antibody development pact with three new targets provided by Brazilian antibody developer Recepta Biopharma SA. The partners will focus their R&D partnership on the generation of three antibodies targeting important cancer immune checkpoints. Under the terms of the agreement, 4-Antibody will use its high-throughput Retrocyte Display® technology platform to generate and produce fully human therapeutic antibody candidates. The Ludwig Institute will validate the new constructs and then, together with Recepta Biopharma, will take these antibody drugs into early clinical testing from 2015 in the US and Brazil.  

4-Antibody and Ludwig jointly will own the antibody drugs while Recepta Biopharma has baged exclusive commercial rights to Brazil in return for undisclosed licensing fees. 4-Antibody will take the lead securing commercialisation partners for the antibody drugs in territories outside Brazil on behalf of itself and Ludwig. Future returns from the collaboration outside of Brazil will be shared among the three parties.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/new-cancer-collaborations.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products